Evidence map›Paper›PMID 38605339›Full record

ReviewBMC cancer2024

Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects.

Lewei Duan, Zheng Liu, Fangning Wan, Bo Dai

Abstract readReview
In one paragraph

Review in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lewei Duan *Department of Urology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China.
Zheng Liu *Department of Urology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China.
Fangning WanDepartment of Urology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China. fnwan06@fudan.edu.cn.
Bo DaiDepartment of Urology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China. bodai1978@126.com.

Funding

Discipline Leader Project of Shanghai Municipal Health Commission 2022XD01Medical Innovation Research Project of the Science and Technology Commission of Shanghai Municipality 20Y11905000National Natural Science Foundation of China 82373355National Nature Science Foundation of China 82172703
6 · The paper itself

Abstract

backgroundWhole-mount histopathology (WMH) has been a powerful tool to investigate the characteristics of prostate cancer. However, the latest advancement of WMH was yet under summarization. In this review, we offer a comprehensive exposition of current research utilizing WMH in diagnosing and treating prostate cancer (PCa), and summarize the clinical advantages of WMH and outlines potential on future prospects.

methodsAn extensive PubMed search was conducted until February 26, 2023, with the search term "prostate", "whole-mount", "large format histology", which was limited to the last 4 years. Publications included were restricted to those in English. Other papers were also cited to contribute a better understanding.

resultsWMH exhibits an enhanced legibility for pathologists, which improved the efficacy of pathologic examination and provide educational value. It simplifies the histopathological registration with medical images, which serves as a convincing reference standard for imaging indicator investigation and medical image-based artificial intelligence (AI). Additionally, WMH provides comprehensive histopathological information for tumor volume estimation, post-treatment evaluation, and provides direct pathological data for AI readers. It also offers complete spatial context for the location estimation of both intraprostatic and extraprostatic cancerous region.

conclusionsWMH provides unique benefits in several aspects of clinical diagnosis and treatment of PCa. The utilization of WMH technique facilitates the development and refinement of various clinical technologies. We believe that WMH will play an important role in future clinical applications.

Indexed as

Artificial IntelligenceProstatic NeoplasmsHumansMagnetic Resonance ImagingMaleProstateAIHistopathologyMRIProstate cancerWhole-mount histopathology

Identifiers

PMID38605339
PMCPMC11007899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.